☆ 4.3 Editorial Material

Germline Testing in Prostate Cancer: Implementation and Disparities of Care

JCO ONCOLOGY PRACTICE (2023)

Journal

JCO ONCOLOGY PRACTICE

Volume 19, Issue 5, Pages 221-+

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1200/OP.22.00804

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Medicine, General & Internal

Comparison of Germline Genetic Testing Before and After a Medical Policy Covering Universal Testing Among Patients With Colorectal Cancer

Chad Moretz, Stacey DaCosta Byfield, Kathryn E. Hatchell, Joline Dalton, Peter Nicholas Onglao, Lillian Hang, Pamela Hansen, Cristi Radford, Sarah M. Nielsen, Brandie Heald, Sandra B. Munro, Robert L. Nussbaum, Edward D. Esplin

Summary: This nationwide cohort study found suboptimal rates of MSI/IHC screening and germline genetic testing uptake in colorectal cancer patients. Clinically actionable genetic data were unavailable to patients despite universal eligibility, highlighting the need for effective strategies to address barriers to implementation of evidence-based testing policies.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Oncology

Germline alterations among Hispanic men with prostate cancer

Elizabeth Pan, Justin Shaya, Lisa Madlensky, J. Michael Randall, Frederick E. Millard, Brent Rose, J. Kellogg Parsons, Sarah M. Nielsen, Kathryn E. Hatchell, Edward D. Esplin, Robert L. Nussbaum, Nicole Weise, James Murphy, Maria Elena Martinez, Rana R. Mckay

Summary: This study aimed to investigate the rate of pathogenic/likely pathogenic germline alterations in Hispanic men with prostate cancer. The results showed that the rate of pathogenic/likely pathogenic germline alterations was similar between Hispanic and non-Hispanic white men, while the rate of variants of uncertain significance was significantly higher in Hispanic men.

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

Add to Collection

Review Urology & Nephrology

Germline testing and genetic counselling in prostate cancer

Jessica Russo, Veda N. Giri

Summary: In this review, the authors discuss the criteria and strategies for germline testing for prostate cancer, as well as the implications for precision medicine and genetic counseling. They highlight the importance of understanding personalized cancer risk management and syndrome-related cancer risk management for optimal care of patients and their families.

NATURE REVIEWS UROLOGY (2022)

Add to Collection

Article Oncology

Disparities in precision medicine-Examining germline genetic counseling and testing patterns among men with prostate cancer

Hala T. Borno, Anobel Y. Odisho, Christine M. Gunn, Magdalena Pankowska, Jennifer R. Rider

Summary: This study found that social factors such as race, age, language proficiency, and insurance status impact the utilization of germline genetic counseling and testing among men with prostate cancer.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)

Add to Collection

Article Oncology

Germline Genetic Testing Among Women ≤45 Years of Age with Ductal Carcinoma In Situ Versus Invasive Breast Cancer in a Large Integrated Health Care System

Diana. S. S. Hsu, Sheng-Fang Jiang, Laurel. A. A. Habel, Elizabeth Hoodfar, Audrey Karlea, Leslie Manace-Brenman, Jessica. M. M. Dzubnar, Veronica. C. C. Shim

Summary: This study compared hereditary cancer multigene panel testing results between patients <= 45 years old with ductal carcinoma in situ (DCIS) and invasive breast cancer (IBC) in a large healthcare system. The study found a lower rate of gene testing among DCIS patients, as well as a lower prevalence of pathogenic variants in BC-related genes compared to IBC patients.

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Disparities in cancer genetics care by race/ethnicity among pan-cancer patients with pathogenic germline variants

Ying L. Liu, Anna Maio, Yelena Kemel, Erin E. Salo-Mullen, Margaret Sheehan, Prince Ray Tejada, Magan Trottier, Angela G. Arnold, Megan Harlan Fleischut, Alicia Latham, Maria Carlo, Yonina R. Murciano-Goroff, Michael F. Walsh, Diana Mandelker, Nikita Mehta, Chaitanya Bandlamudi, Kanika Arora, Ahmet Zehir, Michael F. Berger, David B. Solit, Carol Aghajanian, Luis A. Diaz, Mark E. Robson, Carol L. Brown, Kenneth Offit, Jada G. Hamilton, Zsofia K. Stadler

Summary: The study reveals disparities in genetic counseling among individuals of different backgrounds. Despite high rates of clinically important genetic findings in all groups, Black patients were less likely to receive recommended counseling compared to White patients. Even after removing barriers, non-White, particularly Black patients, were less likely to receive recommended genetics care, which may have implications for their cancer treatment and families.

CANCER (2022)

Add to Collection

Article Oncology

Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer

Stacy Loeb, Veda N. Giri

Summary: Guidelines recommend germline testing for men with metastatic prostate cancer, with varying criteria for testing in localized disease. Genetic testing for localized disease can reveal hereditary cancer risk and may impact future prostate cancer management. The uptake of germline evaluation is not optimal in some practice settings, indicating a need for optimization strategies.

EUROPEAN UROLOGY ONCOLOGY (2021)

Add to Collection

Review Oncology

Racial Differences in Germline Genetic Testing for Prostate Cancer: A Systematic Review

Logan G. Briggs, Grant L. Steele, Zhiyu (Jason) Qian, Sara Subbana, Khalid Y. Alkhatib, Muhieddine Labban, Bjoern J. Langbein, David-Dan Nguyen, Jacqueline Cellini, Kerry Kilbridge, Adam S. Kibel, Quoc-Dien Trinh, Huma Q. Rana, Alexander P. Cole

Summary: Testing for pathogenic variants can help with risk stratification and targeted therapies in oncology. However, there is limited research on access to germline genetic testing (GGT) for Black men and other historically marginalized populations with prostate cancer. This systematic review aimed to identify racial/ethnic disparities in GGT for prostate cancer.

JCO ONCOLOGY PRACTICE (2023)

Add to Collection

Review Oncology

Disparities in germline testing among racial minorities with prostate cancer

Nicole Weise, Justin Shaya, Juan Javier-Desloges, Heather H. Cheng, Lisa Madlensky, Rana R. McKay

Summary: Germline testing is increasingly important in prostate cancer management, especially for high-risk patients. Disparities in germline testing rates among racial/ethnic minorities in the United States must be addressed to reduce inequities in PCa screening and treatment.

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

Add to Collection

Article Oncology

Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients

Francisco Acevedo, Benjamin Walbaum, Mauricio Camus, Manuel Manzor, Sabrina Muniz, Lidia Medina, Militza Petric, Paula Reyes, Francisco Dominguez, Klaus Puschel, Tomas Merino, M. Loreto Bravo, Mauricio P. Pinto, Carolina Ibanez, Kevin Hughes, Cesar Sanchez

Summary: In this study, only 15% of BC patients who met NCCN criteria for germline testing were actually tested, with even lower rates at the public hospital. Factors affecting genetic testing included year of diagnosis, age, family history, disease subtype, and molecular subtype.

BREAST CANCER RESEARCH AND TREATMENT (2023)

Add to Collection

Article Oncology

Genetic testing in prostate cancer management: Considerations informing primary care

Veda N. Giri, Todd M. Morgan, David S. Morris, Jacob E. Berchuck, Colette Hyatt, Mary-Ellen Taplin

Summary: Inherited genetic mutations are closely associated with the risk of prostate cancer, and germline genetic testing plays an important role in determining treatment options and screening high-risk populations. Primary care is a critical field for clinicians to evaluate high-risk patients, individuals with prostate cancer, and survivors who may require germline genetic testing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Urology & Nephrology

Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer

Hong Truong, Kelsey Breen, Subhiksha Nandakumar, Daniel D. Sjoberg, Yelena Kemel, Nikita Mehta, Andrew T. Lenis, Peter A. Reisz, Jessica Carruthers, Nicole Benfante, Vijai Joseph, Aliya Khurram, Anuradha Gopalan, Samson W. Fine, Victor E. Reuter, Andrew J. Vickers, Ozge Birsoy, Ying Liu, Michael Walsh, Alicia Latham, Zsofia K. Stadler, Eugene Pietzak, Behfar Ehdaie, Karim A. Touijer, Vincent P. Laudone, Susan F. Slovin, Karen A. Autio, Daniel C. Danila, Dana E. Rathkopf, James A. Eastham, Yu Chen, Michael J. Morris, Kenneth Offit, David B. Solit, Howard I. Scher, Wassim Abida, Mark E. Robson, Maria I. Carlo

Summary: Tumor-only genomic profiling can help identify germline variants in prostate cancer patients, providing important information for genetic counseling and prioritizing genetic testing.

EUROPEAN UROLOGY (2023)

Add to Collection

Article Oncology

Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study

Dhivya Chandrasekaran, Monika Sobocan, Oleg Blyuss, Rowan E. Miller, Olivia Evans, Shanthini M. Crusz, Tina Mills-Baldock, Li Sun, Rory F. L. Hammond, Faiza Gaba, Lucy A. Jenkins, Munaza Ahmed, Ajith Kumar, Arjun Jeyarajah, Alexandra C. Lawrence, Elly Brockbank, Saurabh Phadnis, Mary Quigley, Fatima El Khouly, Rekha Wuntakal, Asma Faruqi, Giorgia Trevisan, Laura Casey, George J. Burghel, Helene Schlecht, Michael Bulman, Philip Smith, Naomi L. Bowers, Rosa Legood, Michelle Lockley, Andrew Wallace, Naveena Singh, D. Gareth Evans, Ranjit Manchanda

Summary: Multigene testing in ovarian cancer, especially after counselling by multidisciplinary clinical teams, shows a high uptake rate of 97% and identifies a significant proportion of patients with pathogenic variants such as BRCA1/BRCA2, RAD51C/RAD51D/BRIP1. Prospective parallel somatic and germline panel testing is recommended to maximize variant identification in cancer patients.

CANCERS (2021)

Add to Collection

Review Urology & Nephrology

Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care

Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, Scott E. Eggener, Ruth Etzioni, Scarlett L. Gomez, Christopher Haiman, Franklin Huang, Cheryl T. Lee, Mark S. Litwin, Georgios Lyratzopoulos, James L. Mohler, Adam B. Murphy, Curtis Pettaway, Isaac J. Powell, Peter Sasieni, Edward M. Schaeffer, Shahrokh F. Shariat, John L. Gore

Summary: Men of African ancestry have higher rates of prostate cancer mortality, driven by social factors. Addressing this inequality requires a research approach that considers structural, social, environmental, and health factors. However, there are limited studies on interventions to reduce this inequality.

EUROPEAN UROLOGY (2022)

Add to Collection

Article Oncology

Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer

Daniel H. Kwon, Kelly M. Gordon, Barry Tong, Hala T. Borno, Makenna Beigh, Delaire Fattah, Alexandra Schleicher, Rahul R. Aggarwal, Amie M. Blanco, Eric J. Small, Mallika Dhawan

Summary: GTS is a hybrid model of genetic counselor and oncologist delivery that streamlines testing and increases access for men with PCa. It has been found to improve testing completion rates, but does not eliminate racial disparities.

JCO ONCOLOGY PRACTICE (2023)

Add to Collection

Letter Oncology

Impact of Novel Hormonal Therapy on Cognitive Function: Essential to Measure, Difficult to Present Reply

Hannah E. Dzimitrowicz, Andrew J. Armstrong

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND)

Michael R. Harrison, Paul G. Davis, Michel G. Khouri, David B. Bartlett, Rajan T. Gupta, Andrew J. Armstrong, Megan A. McNamara, Tian Zhang, Monika Anand, Kelly Onyenwoke, Sara Edwardson, Danielle Craig, Meghan Michalski, Yuan Wu, Taofik Oyekunle, Brian Coyne, Aubrie Coburn, Lee W. Jones, Daniel J. George

Summary: The study found that supervised exercise prior to and during initial therapy with ADT and enzalutamide can mitigate declines in cardiorespiratory fitness, improve leg strength, and functional capacity for patients with recurrent prostate cancer.

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

Add to Collection

Article Oncology

Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Rahul Aggarwal, Alexander N. Starodub, Brian D. Koh, Guan Xing, Andrew J. Armstrong, Michael A. Carducci

Summary: This study evaluated the safety and efficacy of GS-5829 as a treatment for mCRPC patients. The results showed that the drug was generally tolerated but had limited effectiveness, and there was no clear relationship between dose and plasma concentration.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Editorial Material Oncology

Editor' summary: A paradigm shift in castration-resistant prostate cancer management

Cosimo De Nunzio, Andrew J. Amstrong, Inge Van Oort, Tanya Dorff

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

Add to Collection

Review Oncology

The Value of Phenotypic Precision Medicine in Prostate Cancer

Nathan M. Hawkey, Amanda Broderick, Daniel J. George, Oliver Sartor, Andrew J. Armstrong

Summary: Prostate cancer, the most common cancer among men, can be improved by precision medicine through the use of molecular and genomic biomarkers. However, this benefit is limited to a minority of patients, and phenotypic precision medicine may provide a more individualized approach. This review article discusses the background, clinical benefits, and limitations of genomic and phenotypic precision medicine in prostate cancer.

ONCOLOGIST (2023)

Add to Collection

Review Oncology

Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer

Edina C. Wang, W. Robert Lee, Andrew J. Armstrong

Summary: Recent data suggest that the use of abiraterone acetate and prednisone may improve overall survival, disease-free survival, and metastasis-free survival in men with high-risk localized, node positive, and oligometastatic hormone-sensitive prostate cancer. The addition of potent androgen receptor inhibitors after radiation therapy may be considered after informed decision making.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Add to Collection

Article Medicine, General & Internal

Foreign accent syndrome as a heralding manifestation of transformation to small cell neuroendocrine prostate cancer

Amanda Broderick, Matthew K. Labriola, Neal Shore, Andrew J. Armstrong

Summary: A man with metastatic hormone-sensitive prostate cancer presented with foreign accent syndrome (FAS), characterized by an uncontrollable 'Irish brogue' accent. Despite no Irish background, the FAS was identified as the presenting manifestation of transformation to small cell neuroendocrine prostate cancer (NEPC). The patient's NEPC progressed despite chemotherapy, resulting in brain metastases and likely paraneoplastic ascending paralysis leading to death.

BMJ CASE REPORTS (2023)

Add to Collection

Article Oncology

Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab

Hannah D. McManus, Dylan Zhang, Fides R. Schwartz, Yuan Wu, Jordan Infield, Ethan Ho, Andrew J. Armstrong, Daniel J. George, Danielle Kruse, Rajan T. Gupta, Michael R. Harrison

Summary: Radiographically assessed body composition variables, including muscle and adipose tissue, may serve as prognostic biomarkers in patients with metastatic renal cell carcinoma. Low skeletal muscle index and low subcutaneous adipose tissue index were associated with significantly better progression-free survival.

CLINICAL GENITOURINARY CANCER (2023)

Add to Collection

Article Oncology

Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)

Michael J. Morris, Glenn Heller, David W. Hillman, Olivia Bobek, Charles Ryan, Emmanuel S. Antonarakis, Alan H. Bryce, Olwen Hahn, Himisha Beltran, Andrew J. Armstrong, Lawrence Schwartz, Lionel D. Lewis, Jan H. Beumer, Brooke Langevin, Eric C. McGary, Paul T. Mehan, Amir Goldkorn, Bruce J. Roth, Han Xiao, Colleen Watt, Mary-Ellen Taplin, Susan Halabi, Eric J. Small

Summary: The purpose of this study was to determine whether the addition of abiraterone acetate and prednisone (AAP) to enzalutamide prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the first-line setting. The results showed that the addition of AAP did not provide a statistically significant benefit in OS compared to enzalutamide treatment alone.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Editorial Material Oncology

The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer

Hannah D. Mcmanus, Andrew J. Armstrong

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Susan Halabi, Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher Logothetis, Cora N. Sternberg, Andrew J. Armstrong, Michael A. Carducci, Kim N. Chi, Johann S. de Bono, Daniel P. Petrylak, Karim Fizazi, Celestia S. Higano, Michael J. Morris, Dana E. Rathkopf, Fred Saad, Charles J. Ryan, Eric J. Small, William Kevin Kelly

Summary: This study validated a prognostic model of overall survival in men with metastatic, castration-resistant prostate cancer treated with docetaxel. The model accurately predicts the survival of patients and performs well across different racial, age, and treatment subgroups.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Rewiring of the N-Glycome with prostate cancer progression and therapy resistance

William Butler, Colin McDowell, Qing Yang, Yiping He, Yue Zhao, J. Spencer Hauck, Yinglu Zhou, Hong Zhang, Andrew J. Armstrong, Daniel J. George, Richard Drake, Jiaoti Huang

Summary: The glycome in prostate cancer undergoes significant changes during disease progression and therapy resistance, with specific glycosylation patterns correlating with remission, resistance, recurrence, and neuroendocrine differentiation. These findings have important implications for the diagnosis and treatment of prostate cancer.

NPJ PRECISION ONCOLOGY (2023)

Add to Collection

Article Medicine, Research & Experimental

RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis

Mu-En Wang, Jiaqi Chen, Yi Lu, Alyssa R. Bawcom, Jinjin Wu, Jianhong Ou, John M. Asara, Andrew J. Armstrong, Qianben Wang, Lei Li, Yuzhuo Wang, Jiaoti Huang, Ming Chen

Summary: Inactivation of the RB1 tumor suppressor gene is common in therapy-resistant cancers and predicts poor clinical outcomes. Loss of RB1 and activation of E2F sensitizes cancer cells to ferroptosis, and targeting this pathway with a GPX4 inhibitor inhibits tumor growth and improves survival in RB1-deficient cancers. These findings suggest a promising therapeutic approach for RB1-deficient malignancies.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Add to Collection

Article Andrology

Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen

Zoe D. Michael, Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, Rajan T. Gupta, Steven Patierno, Nadine J. Barrett, Daniel J. George, Glenn M. Preminger, Judd W. Moul, Kevin C. Oeffinger, Kevin Shah, Thomas J. Polascik

Summary: Preliminary outcomes of a multidisciplinary screening algorithm showed that prostate cancer could be detected in a small percentage of men in their forties, highlighting the importance of early risk stratification and detection of high-risk patients.

WORLD JOURNAL OF MENS HEALTH (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.